HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CIR Panel Looks To Establish Guidelines For Read-Across Use

This article was originally published in The Rose Sheet

Executive Summary

At its December meeting in Washington, the Cosmetic Ingredient Review Expert Panel finalized safety assessments for eight ingredients and advanced three other reports. In its reviews, the group made selective use of read-across data while agreeing to discuss protocol for employing the predictive approach in future reviews.

You may also be interested in...



Cosmetic Ingredient Review Report Status

Chart: Data compiled by the Rose Sheet from information in CIR reports and the panel’s Dec. 5-6 meeting.

CIR Panel Plans For Lead Acetate Review At FDA’s Request

While FDA has gone on record as being leery of proposed legislation that would formalize its relationship with the Cosmetic Ingredient Review, the agency continues to leverage the industry-funded program’s expertise. At FDA’s request, the CIR Expert Panel will review progressive hair dye lead acetate in 2017.

ECHA Advises Read-Across Know-How, Only 'Last Resort' Animal Testing

ECHA's progress report on REACH evaluations conducted in 2015 identifies priority targets in its compliance checks and common shortcomings in registrants' dossiers. With new animal testing under the microscope, the agency provides guidance on using (Q)SARs to fill data gaps, as well as insight into its approach to assessing read-across, to assist companies readying for the May 31, 2018 registration deadline.

Related Content

Topics

UsernamePublicRestriction

Register

RS108970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel